- Home
- HHS vs KALA Comparison
HHS vs KALA Comparison
Compare HHS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- KALA
- Stock Information
- Founded
- HHS 1923
- KALA 2009
- Country
- HHS United States
- KALA United States
- Employees
- HHS N/A
- KALA N/A
- Industry
- HHS Advertising
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- KALA Health Care
- Exchange
- HHS Nasdaq
- KALA Nasdaq
- Market Cap
- HHS 28.4M
- KALA 26.2M
- IPO Year
- HHS N/A
- KALA 2017
- Fundamental
- Price
- HHS $3.44
- KALA $7.36
- Analyst Decision
- HHS
- KALA Strong Buy
- Analyst Count
- HHS 0
- KALA 3
- Target Price
- HHS N/A
- KALA $14.00
- AVG Volume (30 Days)
- HHS 8.5K
- KALA 204.0K
- Earning Date
- HHS 08-07-2025
- KALA 08-05-2025
- Dividend Yield
- HHS N/A
- KALA N/A
- EPS Growth
- HHS N/A
- KALA N/A
- EPS
- HHS N/A
- KALA N/A
- Revenue
- HHS $181,355,000.00
- KALA N/A
- Revenue This Year
- HHS $6.54
- KALA N/A
- Revenue Next Year
- HHS N/A
- KALA N/A
- P/E Ratio
- HHS N/A
- KALA N/A
- Revenue Growth
- HHS N/A
- KALA N/A
- 52 Week Low
- HHS $3.06
- KALA $2.92
- 52 Week High
- HHS $8.49
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- HHS 36.41
- KALA 74.24
- Support Level
- HHS $3.20
- KALA $5.35
- Resistance Level
- HHS $3.55
- KALA $8.49
- Average True Range (ATR)
- HHS 0.24
- KALA 0.79
- MACD
- HHS 0.01
- KALA 0.24
- Stochastic Oscillator
- HHS 23.71
- KALA 97.13
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.